Observational retrospective study To characterize and assess clinical outcomes of patients Receiving tezepelumab in the framework Of use in Special Situations prior to commercialisation in Spain - T-ROSS

Inclusion Criteria

• - Subjects 12 years and older with severe asthma who were inadequately controlled with high dose inhaled corticosteroids plus another medicinal product
• - Received at least one dose of tezepelumab under the FMS program, established according to Royal Decree 1015 / 2009 (prior to commercialization)